NVO
Novo Nordisk A/S
NYSE · DKHealthcareDrug Manufacturers - General
$49.61-1.41%
Price as of Jul 20, 2026
NVO financials
Novo Nordisk A/S financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $309.1B | $290.4B | $232.3B | $177.0B |
| Cost of revenue | $58.8B | $44.5B | $35.8B | $28.4B |
| Gross profit | $250.3B | $245.9B | $196.5B | $148.5B |
| Operating expenses | $122.6B | $117.5B | $93.9B | $73.7B |
| Operating income | $127.7B | $128.3B | $102.6B | $74.8B |
| Net income | $102.4B | $101.0B | $83.7B | $55.5B |
| EBITDA | $156.7B | $147.9B | $114.6B | $76.8B |
| Basic EPS | $23.06 | $22.67 | $18.67 | $12.26 |
| Diluted EPS | $23.03 | $22.63 | $18.62 | $12.22 |
| Balance sheet | ||||
| Cash & equivalents | $26.5B | $15.7B | $14.4B | $12.7B |
| Total assets | $542.9B | $465.8B | $314.5B | $241.3B |
| Total liabilities | $348.9B | $322.3B | $207.9B | $157.8B |
| Stockholders’ equity | $194.0B | $143.5B | $106.6B | $83.5B |
| Total debt | $131.0B | $102.8B | $27.0B | $25.8B |
| Net debt | $104.5B | $87.1B | $12.6B | $13.1B |
| Cash flow | ||||
| Operating cash flow | $119.1B | $121.0B | $108.9B | $78.9B |
| Capital expenditure | -$90.1B | -$51.3B | -$38.9B | -$14.8B |
| Free cash flow | $29.0B | $69.7B | $70.0B | $64.1B |
| Dividends paid | -$51.8B | -$44.1B | -$31.8B | -$25.3B |
| Share repurchases | -$1.4B | -$20.2B | -$29.9B | -$24.1B |